1. Scrip
  2. >>Business
  3. >>Financing

Finance Watch: The Growing $100m-Plus VC Club

 
• By Mandy Jackson

Private Company Edition: Venture capital mega-rounds continue to add up, including recent financings for Connect Biopharma ($115m) and Synthego ($100m). Also, Civilization Ventures closed a new $35m fund and Triumvira launched with $55m.

Finance Watch

Venture capital investment in the biopharmaceutical industry continues to be massive in terms of both the number of companies raising funds and the size of funding rounds despite the ongoing economic uncertainty associated with the COVID-19 pandemic. There have been many mega-rounds of $100m or more, including recent financings for Connect Biopharmaceuticals, Ltd. and Synthego Corp.

Immune modulation specialist Connect Biopharmaceuticals, Ltd. announced a $115m series C round 24 August, which was the same day

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

How Teva Is Expanding Innovation To Fuel ‘Pivot To Growth’

 
• By Jessica Merrill

Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By Kevin Grogan

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By Aakash Babu

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.